Department of Pediatric Neurology, Diakonie Kork, Kehl, Germany (C.R.); Department of Radiology (L.A.G., A.T.T., A.J.T.), Division of Neurology (D.A.K., D.N.F.), and Division of Biostatistics and Epidemiology (B.Z.), Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 5031, Cincinnati, OH 45229; and Departments of Radiology (A.T.T., A.J.T.) and Pediatrics (D.A.K., D.N.F., B.Z.), University of Cincinnati College of Medicine, Cincinnati, Ohio.
Radiol Imaging Cancer. 2020 Sep 18;2(5):e190091. doi: 10.1148/rycan.2020190091. eCollection 2020 Sep.
To determine the effect of chronic mammalian target of rapamycin (mTOR) inhibition on skeletal muscle mass in patients with tuberous sclerosis complex (TSC).
In this retrospective study, patients with TSC who were taking mTOR inhibitors and who underwent at least two abdominal CT or MRI examinations between 2005 and 2017 were included ( = 24; 14 males; mean age, 14.5 years ± 7.8 [standard deviation] at first examination). One reviewer drew regions of interest around psoas muscles at L3 to measure cross-sectional area. Multiple linear mixed-effect modeling was performed to evaluate the association between muscle mass and the covariates over time.
The 24 patients underwent a total of 129 abdominal CT or MRI examinations. Median duration of mTOR inhibition at last examination was 106 months (range, 1310-3717 days). There was no significant association between the duration of mTOR inhibitor therapy and psoas muscle area on multiple linear mixed-effect modeling ( = .055); however, patient height and height squared were significant predictors of psoas area ( = .014 and < .0001, respectively).
Duration of mTOR inhibition in TSC was not significantly associated with a decrease in psoas muscle area, suggesting that chronic mTOR inhibition is not associated with sarcopenia. CT, MR-Imaging, Pediatrics© RSNA, 2020.
确定慢性哺乳动物雷帕霉素靶蛋白（mTOR）抑制对结节性硬化症（TSC）患者骨骼肌量的影响。
本回顾性研究纳入了 2005 年至 2017 年间接受 mTOR 抑制剂治疗且至少进行了 2 次腹部 CT 或 MRI 检查的 TSC 患者（n=24；男 14 例；初次检查时的平均年龄为 14.5 岁±7.8〔标准差〕）。一位评估者在 L3 水平勾画竖脊肌的感兴趣区以测量横截面积。采用多元线性混合效应模型评估肌肉量与随时间变化的协变量之间的关系。
24 例患者共进行了 129 次腹部 CT 或 MRI 检查。末次检查时 mTOR 抑制剂治疗的中位持续时间为 106 个月（范围，1310~3717 天）。多元线性混合效应模型显示，mTOR 抑制剂治疗持续时间与竖脊肌面积之间无显著相关性（ =.055）；然而，患者身高和身高平方是竖脊肌面积的显著预测因素（ =.014 和 <.0001）。
TSC 中 mTOR 抑制的持续时间与竖脊肌面积的减少无显著相关性，这表明慢性 mTOR 抑制与肌肉减少症无关。CT、MR 成像、儿科学©RSNA，2020。
